Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
Repligen Corporation (NASDAQ:RGEN) announced its participation in the KeyBanc Life Science and MedTech Investor Forum on March 22-23, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) announced its participation in the KeyBanc Life Science and MedTech Investor Forum on March 22-23, 2022. CEO Tony J. Hunt will engage in a fireside chat on March 22 at 9:45 a.m. EDT. A live webcast of the event will be available on the company’s Investor Relations website and can be replayed for a limited time afterward. Repligen is a leader in bioprocessing technology, supporting biopharmaceutical developers worldwide.
Details
News Market Reaction – RGEN
The recorded move for RGEN in the trading session of this news was +5.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the KeyBanc Life Science and MedTech Investor Forum being held March 22-23, 2022. Tony J. Hunt, President & Chief Executive Officer, will participate in a fireside chat on Tuesday, March 22, at 9:45 a.m. EDT.
A live webcast of the presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, The Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at www.repligen.com. Follow us on LinkedIn and Twitter.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.